AR034585A1 - Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos - Google Patents
Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientosInfo
- Publication number
- AR034585A1 AR034585A1 ARP020101168A ARP020101168A AR034585A1 AR 034585 A1 AR034585 A1 AR 034585A1 AR P020101168 A ARP020101168 A AR P020101168A AR P020101168 A ARP020101168 A AR P020101168A AR 034585 A1 AR034585 A1 AR 034585A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- compounds
- heteroarylalkyl
- arylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de fórmula (1) sus enantiómeros, diastereómeros, sales farmacéuticamente aceptables, profármacos y solvatos de los mismos caracterizado porque: R1 se selecciona del grupo que consiste de hidrógeno, alquilo y cicloalquilo; R2 y R3 son cada uno independientemente seleccionados del grupo que consiste de H, alquilo, arilo, heteroarilo, arilalquilo, cicloalquilo, heterocicloalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo; o R2 y R3 pueden también ser tomados en conjunto para formar un anillo heterocíclico o carbocíclico; R4 se selecciona del grupo que consiste de alquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilo, aminoalquilo, heterocicloalquilalquilo, CN, C(O)R5, CO2R5 y CONR5R6; R5 y R6 son cada uno independientemente seleccionados del grupo que consiste de H, alquilo, cicloalquilo, hidroxialquilo, alquenilo, alcoxi, tioalcoxi, alcoxialquilo, haloalquilo, arilo, heteroarilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo y heterocicloalquilalquilo, o N-R5R6 juntos forman un heterocicloalquilo; Z se selecciona del grupo que consiste de O, S y NR8; R8 se selecciona del grupo que consiste de H, CN, sulfoamido, OR7, alquilo, cicloalquilo, arilo, arilalquilo, heterociclilo, heteroarilo y heteroarilalquilo; y R7 se selecciona del grupo que consiste de H, alquilo, arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo, Los compuestos de fórmula (1) inducen interrupción mitótica haciéndolos con ello útiles como agentes anticancerígenos. Los compuestos de fórmula (1) son también empleados para el tratamiento de otros padecimientos, los cuales pueden ser tratados induciendo interrupción mitótica. Composición farmacéutica y procedimientos para preparar los compuestos de fórmula (1) y los intermediarios.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27995601P | 2001-03-29 | 2001-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR034585A1 true AR034585A1 (es) | 2004-03-03 |
Family
ID=23071059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101168A AR034585A1 (es) | 2001-03-29 | 2002-03-27 | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos |
Country Status (26)
Country | Link |
---|---|
US (1) | US6809102B2 (es) |
EP (1) | EP1373221A4 (es) |
JP (1) | JP2005504725A (es) |
KR (1) | KR20030086327A (es) |
CN (1) | CN1507435A (es) |
AR (1) | AR034585A1 (es) |
BG (1) | BG108180A (es) |
BR (1) | BR0208405A (es) |
CA (1) | CA2442482A1 (es) |
CZ (1) | CZ20032645A3 (es) |
EE (1) | EE200300474A (es) |
HR (1) | HRP20030875A2 (es) |
HU (1) | HUP0400350A3 (es) |
IL (1) | IL157441A0 (es) |
IS (1) | IS6967A (es) |
MX (1) | MXPA03008634A (es) |
NO (1) | NO20034300L (es) |
PE (1) | PE20021013A1 (es) |
PL (1) | PL373759A1 (es) |
RU (1) | RU2003130961A (es) |
SK (1) | SK11062003A3 (es) |
TW (1) | TWI228416B (es) |
UY (1) | UY27232A1 (es) |
WO (1) | WO2002079149A2 (es) |
YU (1) | YU75803A (es) |
ZA (2) | ZA200306648B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6900214B2 (en) * | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
EP1847534B9 (en) * | 2001-12-11 | 2012-03-21 | Kyowa Hakko Kirin Co., Ltd. | Thiadiazoline derivatives for treating cancer |
DK1601673T3 (da) * | 2003-03-07 | 2009-08-24 | Astrazeneca Ab | Kondenserede heterocykler og anvendelser af disse |
AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
EP1616866B1 (en) | 2003-04-18 | 2011-12-14 | Kyowa Hakko Kirin Co., Ltd. | M-stage kinesin inhibitor |
AU2004247551A1 (en) * | 2003-06-10 | 2004-12-23 | Fuji Photo Film Co., Ltd. | Thiadiazoline derivative |
WO2005007124A2 (en) | 2003-07-23 | 2005-01-27 | Bristol-Myers Squibb Company | Substituted dihydropyrimidine inhibitors of calcium channel function |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
US20050282838A1 (en) * | 2003-10-16 | 2005-12-22 | Shyamlal Ramchandani | Compounds, compositions, and methods |
BRPI0513513A (pt) * | 2004-07-22 | 2008-05-06 | Astrazeneca Ab | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito inibitório de eg5 e um efeito anticáncer em um animal de sangue quente, e para tratar carcinomas em um animal de sangue quente |
US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
MX2007001953A (es) * | 2004-08-18 | 2007-05-09 | Astrazeneca Ab | Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer. |
US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
JPWO2006101103A1 (ja) * | 2005-03-22 | 2008-09-04 | 協和醗酵工業株式会社 | 造血器腫瘍治療剤 |
KR20070113300A (ko) * | 2005-03-22 | 2007-11-28 | 교와 핫꼬 고교 가부시끼가이샤 | 고형종양 치료제 |
WO2006137490A1 (ja) * | 2005-06-24 | 2006-12-28 | Kyowa Hakko Kogyo Co., Ltd. | 再狭窄治療剤 |
DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
CN110464722B (zh) * | 2019-06-06 | 2023-05-23 | 暨南大学 | 一类小分子化合物或其药学上可接受的盐在制备抗肿瘤转移药物中的应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6211198B1 (en) | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
SK60097A3 (en) | 1994-11-16 | 1998-01-14 | Synaptic Pharma Corp | Dihydropyrimidines, pharmaceutical composition containing same and use thereof |
WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
US6172066B1 (en) | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
EP1021185A4 (en) | 1996-05-16 | 2005-09-07 | Synaptic Pharma Corp | DIHYDROPYRIMIDINE AND ITS USES. |
US6080760A (en) | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
WO1998057639A1 (en) | 1997-06-18 | 1998-12-23 | Merck & Co., Inc. | ALPHA 1aADRENERGIC RECEPTOR ANTAGONISTS |
WO1999025345A1 (en) | 1997-11-14 | 1999-05-27 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
US6346389B1 (en) | 1998-04-01 | 2002-02-12 | Yale University | Method for selectively modulating the interactions between survivin and tubulin |
US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
EP1226129B1 (en) | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US6284480B1 (en) | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
US6900214B2 (en) | 2001-03-29 | 2005-05-31 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,257 patent/US6809102B2/en not_active Expired - Lifetime
- 2002-03-25 TW TW091105771A patent/TWI228416B/zh not_active IP Right Cessation
- 2002-03-25 PE PE2002000232A patent/PE20021013A1/es not_active Application Discontinuation
- 2002-03-26 BR BR0208405-8A patent/BR0208405A/pt not_active IP Right Cessation
- 2002-03-26 HU HU0400350A patent/HUP0400350A3/hu unknown
- 2002-03-26 MX MXPA03008634A patent/MXPA03008634A/es unknown
- 2002-03-26 JP JP2002577776A patent/JP2005504725A/ja not_active Withdrawn
- 2002-03-26 CA CA002442482A patent/CA2442482A1/en not_active Abandoned
- 2002-03-26 IL IL15744102A patent/IL157441A0/xx unknown
- 2002-03-26 YU YU75803A patent/YU75803A/sh unknown
- 2002-03-26 CZ CZ20032645A patent/CZ20032645A3/cs unknown
- 2002-03-26 CN CNA028074556A patent/CN1507435A/zh active Pending
- 2002-03-26 WO PCT/US2002/009497 patent/WO2002079149A2/en active Search and Examination
- 2002-03-26 EE EEP200300474A patent/EE200300474A/xx unknown
- 2002-03-26 SK SK1106-2003A patent/SK11062003A3/sk unknown
- 2002-03-26 EP EP02728592A patent/EP1373221A4/en not_active Withdrawn
- 2002-03-26 KR KR10-2003-7012604A patent/KR20030086327A/ko not_active Application Discontinuation
- 2002-03-26 PL PL02373759A patent/PL373759A1/xx not_active Application Discontinuation
- 2002-03-26 RU RU2003130961/04A patent/RU2003130961A/ru not_active Application Discontinuation
- 2002-03-27 UY UY27232A patent/UY27232A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101168A patent/AR034585A1/es unknown
-
2003
- 2003-08-26 ZA ZA200306648A patent/ZA200306648B/en unknown
- 2003-09-17 BG BG108180A patent/BG108180A/xx unknown
- 2003-09-18 ZA ZA200307320A patent/ZA200307320B/en unknown
- 2003-09-24 IS IS6967A patent/IS6967A/is unknown
- 2003-09-26 NO NO20034300A patent/NO20034300L/no not_active Application Discontinuation
- 2003-10-28 HR HR20030875A patent/HRP20030875A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20030086327A (ko) | 2003-11-07 |
HUP0400350A2 (hu) | 2005-01-28 |
CZ20032645A3 (cs) | 2004-06-16 |
JP2005504725A (ja) | 2005-02-17 |
BR0208405A (pt) | 2004-03-30 |
HRP20030875A2 (en) | 2004-08-31 |
MXPA03008634A (es) | 2003-12-08 |
IS6967A (is) | 2003-09-24 |
YU75803A (sh) | 2006-05-25 |
US20030008888A1 (en) | 2003-01-09 |
WO2002079149A2 (en) | 2002-10-10 |
CA2442482A1 (en) | 2002-10-10 |
RU2003130961A (ru) | 2005-04-10 |
PE20021013A1 (es) | 2002-11-10 |
HUP0400350A3 (en) | 2005-06-28 |
NO20034300D0 (no) | 2003-09-26 |
BG108180A (en) | 2004-09-30 |
EP1373221A4 (en) | 2004-09-29 |
WO2002079149A3 (en) | 2003-02-27 |
UY27232A1 (es) | 2002-11-29 |
PL373759A1 (en) | 2005-09-05 |
NO20034300L (no) | 2003-11-07 |
SK11062003A3 (sk) | 2004-08-03 |
EP1373221A2 (en) | 2004-01-02 |
ZA200307320B (en) | 2004-12-20 |
ZA200306648B (en) | 2004-11-26 |
CN1507435A (zh) | 2004-06-23 |
EE200300474A (et) | 2003-12-15 |
IL157441A0 (en) | 2004-03-28 |
TWI228416B (en) | 2005-03-01 |
US6809102B2 (en) | 2004-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR052903A1 (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno. | |
AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
AR036107A1 (es) | Derivados de 6-fenilpirrolpirimidindiona, antagonista de los receptores a2 de la adenosina, particularmente del subtipo a2, de aplicacion en la prevencion de la degranulacion de los mastocitos; composiciones farmaceuticas formuladas con dichos compuestos y uso de los mismos en la preparacion de medi | |
AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
AR035777A1 (es) | Derivados de pirazol sustituidos, procesos para su preparacion, composiciones farmaceuticas que los contienen, y su uso en medicina | |
EA200600364A1 (ru) | Производные (тио)карбамоилциклогексана в качестве антагонистов d/dрецептора | |
AR038341A1 (es) | Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l | |
WO2006046031A8 (en) | Pharmaceutical compounds | |
PE20011047A1 (es) | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas | |
AR072545A1 (es) | Fenilpirazinonas como inhibidores de la btk, composicion farmaceutica que las contiene y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades autoinmunes e inflamatorias. | |
PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
AR033379A1 (es) | Compuestos de difenilurea, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
EA200701640A1 (ru) | Новые соединения с терапевтическим эффектом | |
PE20060483A1 (es) | Compuestos heterociclicos como antagonistas de nk1 | |
AR057296A1 (es) | Diarilsulfona sulfonamidas y el uso de las mismas | |
PE20020735A1 (es) | Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b | |
PE20020657A1 (es) | Derivados de amida de piperidinas 1,4-disustituidas de formula (i) | |
AR047958A1 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |